Qiagen announced it will acquire Parse Biosciences for $225 million upfront plus up to $55 million in milestones, marking a strategic move into scalable single‑cell genomics. Parse’s instrument‑free, high‑throughput sample prep technology — used in over 3,000 labs — complements Qiagen’s sample‑to‑insight portfolio and gives the company footholds in single‑cell workflows increasingly demanded by biopharma and academic researchers. Qiagen raised its 2025 earnings guidance alongside the deal and said the acquisition accelerates planned launches of new sample‑preparation instruments. Parse cofounder Alex Rosenberg framed the deal as a path to broader adoption, leveraging Qiagen’s installed base of half a million labs worldwide. Qiagen also announced CEO Thierry Bernard will step down after a successor is appointed, signaling leadership transitions concurrent with the strategic acquisition.